- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8824
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other SGK Inhibitors | GSK650394 PROTAC SGK3 degrader-1 |
|
In vitro |
DMSO
: 73 mg/mL
(200.36 mM)
Ethanol : 73 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 364.34 | Formula | C18H18F2N2O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1181770-72-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCC1=C(C=CC(=C1C)O)C(=O)NNC(=O)C(C2=CC(=CC(=C2)F)F)O | ||
| Targets/IC50/Ki |
SGK1
(Cell-free assay) 3 μM
|
|---|---|
| In vitro |
In vitro testing discloses EMD638683 as a SGK1 inhibitor with an IC50 of 3 μM. This compound treatment significantly augments the radiation‑induced decrease of forward scatter, increase of phosphatidylserine exposure, decrease of mitochondrial potential, increase of caspase 3 activity, increase of DNA fragmentation and increase of late apoptosis. |
| In vivo |
The in vivo development of tumors following chemical carcinogenesis is significantly blunted by treatment with EMD638683. Within 24 hours in vivo this compound treatment significantly decreases blood pressure in fructose/saline-treated mice but not in control animals or in SGK1 knockout mice. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.